CL King upgraded shares of Aratana Therapeutics (NASDAQ:PETX) from a neutral rating to a buy rating in a research report released on Monday, March 12th, MarketBeat Ratings reports. CL King currently has $8.00 target price on the biopharmaceutical company’s stock. The analysts noted that the move was a valuation call.
A number of other equities analysts have also commented on the company. HC Wainwright set a $10.00 price objective on Aratana Therapeutics and gave the stock a buy rating in a research note on Tuesday, January 16th. Zacks Investment Research lowered Aratana Therapeutics from a hold rating to a sell rating in a research note on Wednesday, January 17th. Stifel Nicolaus restated a hold rating and set a $6.00 price objective on shares of Aratana Therapeutics in a research note on Monday, December 18th. ValuEngine lowered Aratana Therapeutics from a sell rating to a strong sell rating in a research note on Sunday, December 31st. Finally, Jefferies Group set a $9.00 price objective on Aratana Therapeutics and gave the stock a buy rating in a research note on Thursday, November 16th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. Aratana Therapeutics has a consensus rating of Hold and an average price target of $8.39.
PETX stock opened at $3.97 on Monday. Aratana Therapeutics has a 52 week low of $3.67 and a 52 week high of $7.67. The company has a debt-to-equity ratio of 0.24, a current ratio of 2.40 and a quick ratio of 2.02.
In other news, insider Craig A. Tooman sold 30,000 shares of Aratana Therapeutics stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $5.27, for a total value of $158,100.00. Following the transaction, the insider now owns 75,024 shares in the company, valued at approximately $395,376.48. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Peter Steven St sold 19,367 shares of Aratana Therapeutics stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $4.77, for a total value of $92,380.59. Following the completion of the transaction, the chief executive officer now owns 672,259 shares in the company, valued at approximately $3,206,675.43. The disclosure for this sale can be found here. Company insiders own 5.20% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the company. MetLife Investment Advisors LLC bought a new position in shares of Aratana Therapeutics in the 4th quarter valued at $110,000. Millennium Management LLC bought a new stake in Aratana Therapeutics during the 4th quarter worth $3,267,000. Ellington Management Group LLC bought a new stake in Aratana Therapeutics during the 4th quarter worth $304,000. Goldman Sachs Group Inc. grew its position in Aratana Therapeutics by 35.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 68,039 shares of the biopharmaceutical company’s stock worth $358,000 after acquiring an additional 17,677 shares during the last quarter. Finally, Deutsche Bank AG grew its position in Aratana Therapeutics by 11.2% during the 4th quarter. Deutsche Bank AG now owns 468,114 shares of the biopharmaceutical company’s stock worth $2,461,000 after acquiring an additional 47,178 shares during the last quarter. Institutional investors own 71.07% of the company’s stock.
About Aratana Therapeutics
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.